UNSPSC 51171529: Betaine hydrate

This classification denotes a nutritional supplement with the molecular formula C5H11NO2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TPU0ITR2BR, chemically known as 1-carboxy-n,n,n-trimethylmethanaminium, chloride but more generally known as betaine hydrate, which bears US NIH Compound Identifier 248.

UNSPSC 51171529 Betaine hydrate is a Commodity code nominally designating a chemical compound used in pharmaceutical and industrial applications, but recent state and local solicitations tagged to this code show little alignment with betaine hydrate itself. The recent opportunities span drug testing specimen collection, therapeutic pharmacy initiatives, and generic pharmaceuticals distribution — none of which center on betaine hydrate as a procured input. The issuing bodies include county criminal justice departments (Collin County Community Supervision and Corrections Department), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The code does not currently reflect meaningful activity in betaine hydrate procurement at the state and local level; instead, it appears to have been applied to broader pharmaceutical and testing services offerings that fall outside the commodity's typical scope.

Geographic activity centers on Texas (Collin County, Texas HHS Commission) and Minnesota (MMCAP, which serves participating state and local facilities including Oregon). Representative recent opportunities include Collin County's RFP 2026-327 for offender specimen collection and drug testing services, posted July 9, 2026, with proposals due July 23, 2026 and an estimated contract value of $600,000 for approximately 25,031 annual tests over two years with three optional one-year renewals; Minnesota's MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026 and effective contract dates of July 1, 2026; and Texas HHS Commission's RFI HHS0017013 posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs. Pursuit under this code should be approached with caution given the mismatch between the commodity designation and actual procurement activity.